Neurological improvement

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028

Patients using statins at stroke onset had significantly greater neurological improvement from admission to 1 month compared to patients not using statins, as measured by change in NIH Stroke Scale.

Effect: improvement; 8.8±4.0 points vs 4.4±5.7 points, p=0.028